Table 3 Number and percentage of patients with adverse events occurring at least 9% more frequently in the idursulfase-treated patients than in placebo-treated patients

From: A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)